Rocket Pharmaceuticals, Inc. Long-term Investments
Rocket Pharmaceuticals, Inc. (RCKT) had Long-term Investments of $0 as of 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:LongTermInvestments · last filed 2025-02-27
- 2024-12-31: Long-term Investments $0.00.
- 2024-09-30: Long-term Investments $0.00.
- 2024-06-30: Long-term Investments $0.00.
- 2024-03-31: Long-term Investments $0.00.
| Period end | Long-term Investments |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-27 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-07 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-06 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-07 |
| 2023-12-31 | $34.32M 10-K · filed 2025-02-27 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-07 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-09 |
| 2023-03-31 | $28.96M 10-Q · filed 2023-05-05 |
| 2022-12-31 | $43.28M 10-K · filed 2024-02-27 |
| 2021-12-31 | $0.00 10-K · filed 2023-02-28 |
| 2019-12-31 | $0.00 10-K · filed 2020-03-06 |
| 2019-09-30 | $0.00 10-Q · filed 2019-11-08 |
| 2019-06-30 | $0.00 10-Q · filed 2019-08-08 |
| 2019-03-31 | $0.00 10-Q · filed 2019-05-09 |
| 2018-12-31 | $7.40M 10-K · filed 2020-03-06 |
| 2018-09-30 | $32.00M 10-Q · filed 2018-11-09 |
| 2018-06-30 | $39.36M 10-Q · filed 2018-08-14 |
| 2017-12-31 | $0.00 10-K · filed 2019-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |